Welcome to the UPF Digital Repository

Description of a European memory clinic cohort undergoing amyloid-PET: the AMYPAD diagnostic and patient management study

Show simple item record

dc.contributor.author Altomare, Daniele
dc.contributor.author Grau-Rivera, Oriol
dc.contributor.author Gispert López, Juan Domingo
dc.contributor.author Minguillón, Carolina
dc.contributor.author Frisoni, Giovanni B.
dc.contributor.author AMYPAD Consortium
dc.date.accessioned 2022-10-05T06:53:45Z
dc.date.available 2022-10-05T06:53:45Z
dc.date.issued 2022
dc.identifier.citation Altomare D, Collij L, Caprioglio C, Scheltens P, van Berckel BNM, Alves IL, et al. Description of a European memory clinic cohort undergoing amyloid-PET: the AMYPAD diagnostic and patient management study. Alzheimers Dement. 2022 Jun 17. DOI: 10.1002/alz.12696
dc.identifier.issn 1552-5260
dc.identifier.uri http://hdl.handle.net/10230/54264
dc.description Data de publicació electrónica: 17-06-2022
dc.description.abstract Introduction: AMYPAD Diagnostic and Patient Management Study (DPMS) aims to investigate the clinical utility and cost-effectiveness of amyloid-PET in Europe. Here we present participants' baseline features and discuss the representativeness of the cohort. Methods: participants with subjective cognitive decline plus (SCD+), mild cognitive impairment (MCI), or dementia were recruited in eight European memory clinics from April 16, 2018, to October 30, 2020, and randomized into three arms: ARM1, early amyloid-PET; ARM2, late amyloid-PET; and ARM3, free-choice. Results: A total of 840 participants (244 SCD+, 341 MCI, and 255 dementia) were enrolled. Sociodemographic/clinical features did not differ significantly among recruiting memory clinics or with previously reported cohorts. The randomization assigned 35% of participants to ARM1, 32% to ARM2, and 33% to ARM3; cognitive stages were distributed equally across the arms. Discussion: the features of AMYPAD-DPMS participants are as expected for a memory clinic population. This ensures the generalizability of future study results.
dc.description.sponsorship This communication reflects the views of the authors and neither the Innovative Medicines Initiative (IMI) nor the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA) are liable for any use that may be made of the information contained herein. The Geneva Memory Center is funded by the following private donors under the supervision of the Private Foundation of Geneva University Hospitals: A.P.R.A. - Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Genève; Fondation Segré, Genève; Ivan Pictet, Genève; Fondazione Agusta, Lugano; Fondation Chmielewski, Genève. Competitive research projects have been funded by: H2020, Human Brain Project, Innovative Medicines Initiative (IMI), IMI2, Swiss National Science Foundation, VELUX Foundation. External sites affiliated with CHUT: Françoise Desclaux (Geriatrics department of Lavaur), Marie-Noelle Cufi (Geriatrics department of Lavaur), and Jérémie Pariente (department of Neurology of Toulouse University Hospital, Inserm Toulouse NeuroImaging Center, Université Paul Sabatier, Centre d'Investigation Clinique de Toulouse CIC 1436). The BBRC's memory center received funding from the Barcelona City Council (agreement # 20XC0354) and Biogen. Daniele Altomare received funding from the Fondation Recherche Alzheimer and the Swiss National Science Foundation (project CRSK-3_196354/1). Camilla Caprioglio was supported by EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952). Johannes Berkhof is a recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106), and received funding from the EU (AMYPAD, RISCC), ZonMW (HPV compare), WHO, IARC, and RIVM. Valentina Garibotto was supported by the Swiss National Science Foundation (projects 320030_169876, 320030_185028 and IZSEZ0_188355), by the Velux Foundation (project 1123), by the Schmidheiny foundation, and by the Aetas foundation. Oriol Grau-Rivera received funding from Alzheimer's Association (2019-AARF-644568) and Instituto de Salud Carlos III (PI19/00117). Juan Domingo Gispert is supported by the Spanish Ministry of Science and Innovation (RYC-2013-13054) and received funding from the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952). Alexander Drzezga received funding by Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952), DFG (Deutsche Forschungsgemeinschaft), BMBF (Bundesministerium für Bildung und Forschung), EFRE/Leitmarkt (Europäischen Fonds für regionale Entwicklung), University of Cologne, Forschungszentrum Jülich. Novartis clinical trial. Claus Escher received funding from the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) European Prevention of Alzheimer's Dementia consortium (EPAD, grant agreement number: 115736) and Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952). Frank Jessen received funding from BMBF, DFG, H2020, and IMI. Agneta Nordberg received funding from Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952), Swedish Foundation for Strategic Research (RB12-01929), Swedish Research Council (2017-06086, 2017-02965, 2020-019909, CIMED, Swedish Brain Foundation, Swedish Alzheimer foundation, Recherche Sur Alzheimer Fondation, France, and Michael J Fox Foundation (MJFF-019728). Zuzana Walker received funding from HTA-NIHR, Lewy body Society, and ARUK. Jean-François Demonet received funding from Biogen “EMBARK” study, Empiris foundation, Solis foundation, OM Pharma, and Leenaards foundation. Frederik Barkhof is supported by the NIHR Biomedical Research Centre at University College London Hospitals. Giovanni B. Frisoni received funding from the EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU) European Prevention of Alzheimer's Dementia consortium (EPAD, grant agreement number: 115736) and Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD, grant agreement number: 115952); the Swiss National Science Foundation (COSCODE, grant number: 320030_182772); A.P.R.A. - Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Genève; Fondation Segré, Genève; Ivan Pictet, Genève; Fondazione Agusta, Lugano; Fondation Chmielewski, Genève; and VELUX Foundation. Open access funding provided by Universite de Geneve.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Wiley
dc.rights This is an open access article under the terms of the Creative Commons Attribution- Non Commercial License http://creativecommons.org/licenses/by-nc/4.0/, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. ©2022 The Authors. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.
dc.title Description of a European memory clinic cohort undergoing amyloid-PET: the AMYPAD diagnostic and patient management study
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1002/alz.12696
dc.subject.keyword Alzheimer's
dc.subject.keyword PET
dc.subject.keyword Amyloid
dc.subject.keyword Dementia
dc.subject.keyword Memory clinic population
dc.subject.keyword Mild cognitive impairment
dc.subject.keyword Subjective cognitive decline
dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/115952
dc.relation.projectID info:eu-repo/grantAgreement/EC/FP7/115736
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking